NYSE · LLY
Eli Lilly and Company
$1,431.66+$57.96 (+4.22%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
OTC · CRXTQ · USD
Stock price, earnings
Quote as of Feb 28, 2023, 08:06 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Clarus Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Clarus Therapeutics Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,431.66+$57.96 (+4.22%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$276.50+$1.30 (+0.47%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.0% below the high.
$0.00$0.00 (0.0%)
PotNetwork Holdings, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Predictive Technology Group, Inc.: Healthcare · Biotechnology.
$0.00-$0.00 (-25.0%)
Invitae Corporation: Healthcare · Medical - Diagnostics & Research.
$0.00$0.00 (0.0%)
Nexeon MedSystems Inc.: Healthcare · Medical - Devices.
$0.00$0.00 (0.0%)
Health-Chem Corporation: Healthcare · Medical - Diagnostics & Research.
$0.01-$0.00 (-7.41%)
Unrivaled Brands, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.79% below the high.
